Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a hold rating to a buy rating in a research report report published on Friday morning. They currently have $5.25 price target on the biopharmaceutical company’s stock.
According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “
BLCM has been the subject of several other research reports. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, July 25th. Cantor Fitzgerald set a $18.00 target price on shares of Bellicum Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, August 7th. Citigroup dropped their target price on shares of Bellicum Pharmaceuticals from $22.00 to $19.00 and set a buy rating for the company in a research report on Thursday, August 9th. Finally, ValuEngine raised shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $13.42.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.03. The company had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.07 million. As a group, sell-side analysts expect that Bellicum Pharmaceuticals will post -2.4 earnings per share for the current fiscal year.
In related news, CTO David M. Spencer sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $7.04, for a total transaction of $70,400.00. Following the completion of the sale, the chief technology officer now owns 89,939 shares of the company’s stock, valued at approximately $633,170.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. 9.84% of the stock is owned by corporate insiders.
Several large investors have recently made changes to their positions in BLCM. Frazier Management LLC bought a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter valued at about $7,760,000. BlackRock Inc. grew its position in shares of Bellicum Pharmaceuticals by 37.5% during the 2nd quarter. BlackRock Inc. now owns 3,112,394 shares of the biopharmaceutical company’s stock valued at $22,970,000 after buying an additional 849,208 shares during the last quarter. Wasatch Advisors Inc. grew its position in shares of Bellicum Pharmaceuticals by 1,004.4% during the 2nd quarter. Wasatch Advisors Inc. now owns 923,824 shares of the biopharmaceutical company’s stock valued at $6,818,000 after buying an additional 840,175 shares during the last quarter. Millennium Management LLC grew its position in shares of Bellicum Pharmaceuticals by 198.5% during the 2nd quarter. Millennium Management LLC now owns 733,850 shares of the biopharmaceutical company’s stock valued at $5,416,000 after buying an additional 487,982 shares during the last quarter. Finally, ARK Investment Management LLC grew its position in shares of Bellicum Pharmaceuticals by 108.0% during the 3rd quarter. ARK Investment Management LLC now owns 590,214 shares of the biopharmaceutical company’s stock valued at $3,636,000 after buying an additional 306,442 shares during the last quarter. 59.26% of the stock is owned by institutional investors and hedge funds.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Featured Story: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.